| Symbol | BLRX |
|---|---|
| Name | BIOLINE RX LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | BIOMED |
| Address | 2 HAMAAYAN STREET, MODIIN, 7177871, Israel |
| Telephone | 08-6429100 |
| Fax | 08-6429101 |
| info@biolinerx.com | |
| Website | www.biolinerx.com |
| Incorporation | Israel |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | TASE;NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions. Additional info from NASDAQ: |
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Read moreNew Form 3 - BioLineRx Ltd. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001178913-26-002057 <b>Size:</b> 3 KB
Read moreHemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
Read moreNew Form 3 - BioLineRx Ltd. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001178913-26-001963 <b>Size:</b> 15 KB
Read moreNew Form 3 - BioLineRx Ltd. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001178913-26-001961 <b>Size:</b> 16 KB
Read moreNew Form 3 - BioLineRx Ltd. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001178913-26-001959 <b>Size:</b> 8 KB
Read moreNew Form 3 - BioLineRx Ltd. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001178913-26-001958 <b>Size:</b> 16 KB
Read moreNew Form 3 - BioLineRx Ltd. <b>Filed:</b> 2026-03-30 <b>AccNo:</b> 0001178913-26-001893 <b>Size:</b> 5 KB
Read more